Cystic fibrosis sputum - A barrier to the transport of nanospheres

被引:208
作者
Sanders, NN
De Smedt, SC
Van Rompaey, E
Simoens, P
De Baets, F
Demeester, J
机构
[1] State Univ Ghent, Fac Pharm, Gen Biochem & Phys Pharm Labs, B-9000 Ghent, Belgium
[2] State Univ Ghent, Fac Vet Med, B-9000 Ghent, Belgium
[3] State Univ Ghent, Fac Med, B-9000 Ghent, Belgium
关键词
D O I
10.1164/ajrccm.162.5.9909009
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Cystic fibrosis (CF) is characterized by the presence of a viscoelastic mucus layer in the upper airways and bronchi. The underlying problem is a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein. Clinical studies of gene transfer for CF are ongoing. For gene delivery to the airways of CF patients to be effective, the mucus covering the target cells must be overcome. We therefore examined the extent to which CF sputum presents a physical barrier to the transport of nanospheres of a size comparable to that of lipoplexes and other transfection systems currently being clinically evaluated for CF gene therapy. We observed that an extremely low percentage of nanospheres (< 0.3%) moved through a 220-<mu>m-thick CF sputum layer after 150 min. The largest nanospheres studied (560 nm) were almost completely blocked by the sputum, whereas the smaller nanospheres (124 nm) were retarded only by a factor of 1.3 as compared with buffer. Surprisingly, the nanospheres diffused significantly more easily through the more viscoelastic sputum samples. We hypothesize that the structure of the network in sputum becomes more macroporous when the sputum becomes more viscoelastic. Sputum from a patient with chronic obstructive pulmonary disease retarded the transport of nanospheres to the same extent as did CF sputum. When directly mixed with CF sputum, recombinant human deoxyribonuclease I moderately facilitated the transport of nanospheres through CF sputum.
引用
收藏
页码:1905 / 1911
页数:7
相关论文
共 30 条
[11]   ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo [J].
Ferrari, S ;
Moro, E ;
Pettenazzo, A ;
Behr, JP ;
Zacchello, F ;
Scarpa, M .
GENE THERAPY, 1997, 4 (10) :1100-1106
[12]   Cystic fibrosis clinical trials [J].
Geddes, D ;
Alton, E .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 30 (1-3) :205-217
[13]  
GIROD S, 1992, EUR RESPIR J, V5, P477
[14]   PHOSPHOLIPID-COMPOSITION AND SURFACE-ACTIVE PROPERTIES OF TRACHEOBRONCHIAL SECRETIONS FROM PATIENTS WITH CYSTIC-FIBROSIS AND CHRONIC OBSTRUCTIVE PULMONARY-DISEASES [J].
GIROD, S ;
GALABERT, C ;
LECUIRE, A ;
ZAHM, JM ;
PUCHELLE, E .
PEDIATRIC PULMONOLOGY, 1992, 13 (01) :22-27
[15]  
JACQUOT J, 1992, EUR RESPIR J, V5, P343
[16]   The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium [J].
Kitson, C ;
Angel, B ;
Judd, D ;
Rothery, S ;
Severs, NJ ;
Dewar, A ;
Huang, L ;
Wadsworth, SC ;
Cheng, SH ;
Geddes, DM ;
Alton, EWFW .
GENE THERAPY, 1999, 6 (04) :534-546
[17]  
Lee RJ, 1997, CRIT REV THER DRUG, V14, P173
[18]   SCATTERING AND SWELLING PROPERTIES OF INHOMOGENEOUS POLYACRYLAMIDE GELS [J].
MALLAM, S ;
HORKAY, F ;
HECHT, AM ;
GEISSLER, E .
MACROMOLECULES, 1989, 22 (08) :3356-3361
[19]  
MIQUEL JF, 1995, J LIPID RES, V36, P2450
[20]   Distribution of DNA and alginate in purulent cystic fibrosis sputum: Implications to pulmonary targeting strategies [J].
Mrsny, RJ ;
Daugherty, AL ;
Short, SM ;
Widmer, R ;
Siegel, MW ;
Keller, GA .
JOURNAL OF DRUG TARGETING, 1996, 4 (04) :233-243